Form 4: Corbus Pharmaceuticals Director Anne Altmeyer Receives Stock Grant

Director Anne Altmeyer of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Summary

• Anne Altmeyer, a director at Corbus Pharmaceuticals Holdings, Inc., received 2,783 restricted stock units (RSUs) on May 30, 2024.
• These RSUs will vest 100% on the one-year anniversary of the grant date.
• The RSUs will be settled in shares of common stock with a par value of $0.0001.
• A Power of Attorney was executed on February 29, 2024, granting Yuval Cohen, Sean Moran, and Meghan Houghton the authority to act on behalf of Anne Altmeyer for SEC filings related to Corbus Pharmaceuticals Holdings, Inc.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock units, which is generally viewed positively as it aligns the director's interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• RSU grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (2,783 RSUs) would need to be compared against grants to directors at similarly sized pharmaceutical companies to assess its relative value.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation for their board members.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• The grant has a minimal immediate impact on employees, customers, suppliers, and creditors.

Key Dates